XERS - Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M
2023-10-16 14:13:43 ET
More on Xeris Pharmaceuticals
- Xeris Biopharma Holdings: On Track To Be Cash Flow Positive
- Xeris Biopharma's Financial Pathway: Growth Amid Challenges
- Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Earnings Call Transcript
- Xeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01, revenue of $38.01M beats by $3.17M
- Seeking Alpha’s Quant Rating on Xeris Pharmaceuticals
For further details see:
Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M